News

Verve Therapeutics wins FDA fast track status for cholesterol treatment
Verve Therapeutics (NASDAQ:VERV) stock gains as the company wins the FDA fast track designation for VERVE-102, a cholesterol ...
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
In addition, in the second half of 2025, Verve remains on track to report the final data for the dose escalation portion of the Heart-2 clinical trial, deliver the opt-in package for the PCSK9 program ...
Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe
Argenx (ARGX) stock rises as the FDA approves Vyvgart Hytrulo developed with Halozyme (HALO) for self-injection, the drug's ...
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...